Condition: Nonsmall Cell Lung Cancer Stage III · Unresectable Non-Small Cell Lung Carcinoma · Nonsmall Cell Lung Cancer, Stage II · Sponsor: Wake Forest University Health Sciences
This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
This description comes directly from the study's public registry record.
Jada Kluttz · 336-713-0901 · Jada.Kluttz@Advocatehealth.org
Always discuss trial participation with your own doctor first.
| Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05696782